JP2023513013A5 - - Google Patents
Info
- Publication number
- JP2023513013A5 JP2023513013A5 JP2022545994A JP2022545994A JP2023513013A5 JP 2023513013 A5 JP2023513013 A5 JP 2023513013A5 JP 2022545994 A JP2022545994 A JP 2022545994A JP 2022545994 A JP2022545994 A JP 2022545994A JP 2023513013 A5 JP2023513013 A5 JP 2023513013A5
- Authority
- JP
- Japan
- Prior art keywords
- iacs
- cancer
- nrg1
- fusion
- quinazoline
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062967282P | 2020-01-29 | 2020-01-29 | |
| US62/967,282 | 2020-01-29 | ||
| PCT/US2021/015704 WO2021155144A1 (en) | 2020-01-29 | 2021-01-29 | Use of quinazoline-based tyrosine kinase inhibitors for the treatment of cancers with nrg1 fusions |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023513013A JP2023513013A (ja) | 2023-03-30 |
| JP2023513013A5 true JP2023513013A5 (https=) | 2024-01-17 |
| JP7734139B2 JP7734139B2 (ja) | 2025-09-04 |
Family
ID=77079970
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022545994A Active JP7734139B2 (ja) | 2020-01-29 | 2021-01-29 | Ｎｒｇ１融合体を有するがんの治療のためのキナゾリンベースのチロシンキナーゼインヒビターの使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230121116A1 (https=) |
| EP (1) | EP4097140A4 (https=) |
| JP (1) | JP7734139B2 (https=) |
| KR (1) | KR20220133927A (https=) |
| CN (1) | CN115427456A (https=) |
| CA (1) | CA3166298A1 (https=) |
| WO (1) | WO2021155144A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024523001A (ja) * | 2021-06-03 | 2024-06-25 | メルス ナムローゼ フェンノートシャップ | 新たなｎｒｇ１融合体、融合接合部及びそれらを検出するための方法 |
| WO2022266426A1 (en) * | 2021-06-17 | 2022-12-22 | Black Diamond Therapeutics, Inc. | 6-(heterocycloalkyl-oxy)-quinazoline derivatives and uses thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI377944B (en) * | 2007-06-05 | 2012-12-01 | Hanmi Holdings Co Ltd | Novel amide derivative for inhibiting the growth of cancer cells |
| WO2009042618A1 (en) * | 2007-09-24 | 2009-04-02 | Tragara Pharmaceuticals, Inc. | Therapies for treating cancer using combinations of cox-2 inhibitors and anti-her2(erbb2) antibodies or combinations of cox-2 inhibitors and her2(erbb2) receptor tyrosine kinase inhibitors |
| CN103547598A (zh) | 2011-02-24 | 2014-01-29 | 梅里麦克制药股份有限公司 | 包含抗-erbb3药剂的联合治疗 |
| WO2013113796A1 (en) | 2012-01-31 | 2013-08-08 | Smithkline Beecham (Cork) Limited | Method of treating cancer |
| EP2924045A1 (en) * | 2014-03-25 | 2015-09-30 | Medizinische Universität Wien | New agents for the treatment of cancer |
| WO2016201454A1 (en) * | 2015-06-12 | 2016-12-15 | The Translational Genomics Research Institute | Targeted therapies for cancer |
| KR102771603B1 (ko) * | 2016-11-17 | 2025-02-24 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | Egfr 또는 her2 엑손 20 돌연변이를 갖는 암 세포에 대한 항종양 활성을 갖는 화합물 |
| EP3679063A4 (en) * | 2017-09-08 | 2021-06-02 | The Regents of The University of Colorado, A Body Corporate | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATMENT OR PREVENTION OF HER-CONTROLLED DRUG-RESISTANT CANCER |
| CN112040952B (zh) * | 2018-02-20 | 2023-03-31 | 苏州韬略生物科技股份有限公司 | 用作激酶抑制剂的取代的喹啉 |
| KR20210025064A (ko) * | 2018-06-25 | 2021-03-08 | 스펙트럼 파마슈티컬즈 인크 | 항-her1, her2 또는 her4 항체와 포지오티닙의 조합물 및 이의 사용 방법 |
| JP7777533B2 (ja) * | 2020-01-29 | 2025-11-28 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | Ｎｒｇ１融合体を有するがんの治療のためのポジオチニブの使用 |
-
2021
- 2021-01-29 WO PCT/US2021/015704 patent/WO2021155144A1/en not_active Ceased
- 2021-01-29 EP EP21748276.9A patent/EP4097140A4/en active Pending
- 2021-01-29 CN CN202180026290.5A patent/CN115427456A/zh active Pending
- 2021-01-29 KR KR1020227029158A patent/KR20220133927A/ko active Pending
- 2021-01-29 US US17/759,817 patent/US20230121116A1/en active Pending
- 2021-01-29 CA CA3166298A patent/CA3166298A1/en active Pending
- 2021-01-29 JP JP2022545994A patent/JP7734139B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Gala et al. | Molecular pathways: HER3 targeted therapy | |
| Meric-Bernstam et al. | Advances in HER2-targeted therapy: novel agents and opportunities beyond breast and gastric cancer | |
| Moasser | Targeting the function of the HER2 oncogene in human cancer therapeutics | |
| de Bono et al. | The ErbB receptor family: a therapeutic target for cancer | |
| Gunturu et al. | Gastric cancer and trastuzumab: first biologic therapy in gastric cancer | |
| JP2006508336A5 (https=) | ||
| Maggiore et al. | The older adult with locoregionally advanced head and neck squamous cell carcinoma: knowledge gaps and future direction in assessment and treatment | |
| Juric et al. | Safety and pharmacokinetics/pharmacodynamics of the first-in-class dual action HER3/EGFR antibody MEHD7945A in locally advanced or metastatic epithelial tumors | |
| Hajj et al. | Role of radiotherapy and newer techniques in the treatment of GI cancers | |
| Mendelsohn | Antibody-mediated EGF receptor blockade as an anticancer therapy: from the laboratory to the clinic | |
| Kim et al. | EGFR and HER3 signaling blockade in invasive mucinous lung adenocarcinoma harboring an NRG1 fusion | |
| JP2023513013A5 (https=) | ||
| Francis et al. | Pan-HER inhibitor augments radiation response in human lung and head and neck cancer models | |
| Vaquero et al. | Genetic alterations shaping tumor response to anti-EGFR therapies | |
| JP2023512237A5 (https=) | ||
| Jasra et al. | A rare case of S310F somatic ERBB2 mutation in a HER2-nonamplified breast cancer | |
| Chua et al. | Stereotactic radiosurgery versus gold grain implantation in salvaging local failures of nasopharyngeal carcinoma | |
| JP2023513006A5 (https=) | ||
| Fornaro et al. | Cetuximab plus irinotecan after irinotecan failure in elderly metastatic colorectal cancer patients: clinical outcome according to KRAS and BRAF mutational status | |
| Shirai et al. | Molecular targets in squamous cell carcinoma of the head and neck | |
| Zhang et al. | Anatomical localization of p53 mutated tumors: a radiographic study of human glioblastomas | |
| Takahashi et al. | LJM716 in Japanese patients with head and neck squamous cell carcinoma or HER2-overexpressing breast or gastric cancer | |
| CN105407916A (zh) | 二价疫苗组合物以及其用于治疗肿瘤的用途 | |
| Longo et al. | Bay846, a new irreversible small molecule inhibitor of EGFR and Her2, is highly effective against malignant brain tumor models | |
| Fang et al. | Immunohistochemical expression of epidermal growth factor receptor and cyclooxygenase-2 in pediatric nasopharyngeal carcinomas: no significant correlations with clinicopathological variables and treatment outcomes |